glp 1 cardiovascular disease Bridging the gap between GLP1-receptor agonists and outcomes: evidence for the role of tirzepatide | Cardiovascular Diabetology The Cardiovascular Physiology of Glucagon-like
Description
Stinissen P, Medaer R, Raus J (1998) Myelin reactive T cells in the autoimmune pathogenesis of multiple sclerosis
GLP-1 agonists may be used alone in patients intolerant of metformin or in combination with metformin, thiazolidinediones, and sulfonylureas (or in any combination thereof)
48:S181-S206 [PMC free article: PMC11635045] [PubMed: 39651989] 9
AUTHOR CONTRIBUTIONS B.J
